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Abstract: Mx proteins are interferon (IFN) type I (฀/฀)- and type III (฀)-induced effector proteins with
intrinsic antiviral activity. Mammalian Mx proteins show different subcellular localizations and distinct
yet partially overlapping viral specificities. However, the precise mechanism(s) of antiviral action are
still unresolved. Human MxA accumulates in the cytoplasm and inhibits a wide variety of RNA and
DNA viruses, among them influenza A virus (IAV). In contrast, MxB, the second human Mx protein,
localizes via its amino (N) terminus to the outer nuclear membrane at or near nuclear pores and inhibits
the nuclear import of incoming human immunodeficiency viruses (HIV) and herpesviruses, but not that
of IAV. Here, we evaluated whether the antiviral specificity of MxB is determined by its subcellular
localization. For this purpose, we redirected MxB to the nucleus or cytoplasm by either attaching a
nuclear localization signal to its N terminus or by exchanging the N terminus of MxB with that of MxA.
Interestingly, ectopic expression of these MxB variants in the nucleus or in the cytoplasm rendered the
host cells resistant to IAV, revealing that the capacity of MxB to block IAV replication critically depends
on the site where the protein accumulates in the infected cell. Furthermore, coimmunoprecipitation
(co-IP) assays demonstrated that MxB physically interacted with the nucleoprotein (NP) of IAV. Taken
together, the data indicate that the subcellular localization of the MxB protein plays a pivotal role in
determining its antiviral specificity.IMPORTANCE The interferon system plays a pivotal role in the
defense against viral infections. The dynamin-related Mx proteins form a small family of interferon-
induced effector proteins with distinct antiviral specificities and subcellular localizations. So far, it is
not clear whether the different virus specificities of Mx proteins are the result of distinct mechanisms
of action or are due rather to their different subcellular localization. We show here that the human
MxB protein, normally localized to the outer membrane of the cell nucleus, acquires antiviral activity
against IAV when redirected to the nucleus or cytoplasm, subcellular sites where other members of the
Mx protein family efficiently interfere with IAV replication. Our findings thus strongly suggest that Mx
proteins act primarily through a common mechanism and that their viral specificity is at least in part
determined by their individual subcellular localization.
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ABSTRACT Mx proteins are interferon (IFN) type I (/)- and type III ()-induced ef-
fector proteins with intrinsic antiviral activity. Mammalian Mx proteins show different
subcellular localizations and distinct yet partially overlapping viral specificities. How-
ever, the precise mechanism(s) of antiviral action are still unresolved. Human MxA
accumulates in the cytoplasm and inhibits a wide variety of RNA and DNA viruses,
among them influenza A virus (IAV). In contrast, MxB, the second human Mx protein,
localizes via its amino (N) terminus to the outer nuclear membrane at or near nu-
clear pores and inhibits the nuclear import of incoming human immunodeficiency
viruses (HIV) and herpesviruses, but not that of IAV. Here, we evaluated whether the
antiviral specificity of MxB is determined by its subcellular localization. For this pur-
pose, we redirected MxB to the nucleus or cytoplasm by either attaching a nuclear
localization signal to its N terminus or by exchanging the N terminus of MxB with
that of MxA. Interestingly, ectopic expression of these MxB variants in the nucleus or
in the cytoplasm rendered the host cells resistant to IAV, revealing that the capacity
of MxB to block IAV replication critically depends on the site where the protein ac-
cumulates in the infected cell. Furthermore, coimmunoprecipitation (co-IP) assays
demonstrated that MxB physically interacted with the nucleoprotein (NP) of IAV.
Taken together, the data indicate that the subcellular localization of the MxB protein
plays a pivotal role in determining its antiviral specificity.
IMPORTANCE The interferon system plays a pivotal role in the defense against viral
infections. The dynamin-related Mx proteins form a small family of interferon-
induced effector proteins with distinct antiviral specificities and subcellular localiza-
tions. So far, it is not clear whether the different virus specificities of Mx proteins are
the result of distinct mechanisms of action or are due rather to their different sub-
cellular localization. We show here that the human MxB protein, normally localized
to the outer membrane of the cell nucleus, acquires antiviral activity against IAV
when redirected to the nucleus or cytoplasm, subcellular sites where other members
of the Mx protein family efficiently interfere with IAV replication. Our findings thus
strongly suggest that Mx proteins act primarily through a common mechanism and
that their viral specificity is at least in part determined by their individual subcellular
localization.
KEYWORDS Mx proteins, MxB, influenza A viruses, interferon system, subcellular
localization, viral specificity
Mx proteins are dynamin-related GTPases that play key roles in the interferon typeI- and type III-mediated innate immune response against a variety of viruses
(reviewed in references 1 and 2). They interfere with the replication of many RNA and
DNA viruses by inhibiting early steps of their life cycle. The two MX genes (MX1 and
MX2) of the human genome encode the two proteins MxA and MxB (also termed Mx1
and Mx2). The MxA protein restricts a broad spectrum of viruses, primarily negative-
stranded RNA viruses, but also some positive-stranded RNA viruses and DNA viruses (for
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a review, see reference 3). The subcellular localization determines in part the antiviral
specificity of Mx proteins (4, 5). MxB has recently been shown to inhibit the replication
of primate (nonhuman and human) lentiviruses, herpesviruses, and cyclophilin
A-dependent flaviviruses (6–12). Mammalian Mx proteins accumulate in different sub-
cellular compartments. Human MxA accumulates in the cytoplasm and has been
reported to be partly associated with the plasma membrane, as well as with the smooth
endoplasmic reticulum, but it can also be found in metastable membraneless cytoplas-
mic condensates and was shown to form inflammasomes in cells of the respiratory
epithelium (13–16). MxB exists in at least two isoforms of 715 and 690 amino acids. The
longer isoform represents the full-length form, which includes an N-terminal nuclear
localization signal (NLS), while the shorter isoform is translated from a downstream
translation start site and lacks the NLS (17, 18). The full-length MxB is localized primarily
on the cytoplasmic face of the nuclear membranes, but when expressed ectopically it
can also be found in the cytoplasm or in the nucleus in a granular pattern in the
heterochromatin region beneath the nuclear envelope (6, 18, 19). The short isoform is
expressed in the cytoplasm (20, 21) and does not exhibit any known antiviral activity (6,
11, 22).
The mouse genome carries two Mx genes encoding nuclear Mx1 and cytoplasmic
Mx2 (23, 24). Mouse Mx1 protein contains an NLS in the carboxy (C)-terminal region and
is thus exclusively expressed in the cell nucleus (24, 25). Mouse Mx1 inhibits members
of the orthomyxovirus family, including influenza A virus (IAV), which replicates in the
cell nucleus. In contrast, Mx2 restricts vesicular stomatitis virus (VSV) and hantavirus,
both negative-stranded RNA viruses that replicate in the cytoplasm (4, 23, 26). Intrigu-
ingly, human MxA restricts not only various RNA viruses replicating in the cytoplasm
such as VSV, La Crosse virus, or Semliki forest virus (SFV), but also several members of
the orthomyxoviruses, including IAV (reviewed in references 1 and 3). Mx proteins
require a functional G domain to inhibit Mx-sensitive viruses; exceptions are MxB when
targeting lentiviruses (7) and MxA blocking hepatitis B virus (HBV) (27). Although the
viral targets of Mx proteins are known for many Mx-sensitive viruses to be nucleopro-
teins, viral ribonucleoprotein (vRNP) complexes or nucleocapsids (reviewed in refer-
ences 1 and 3), the molecular mechanism(s) of action of Mx proteins remain to be
elucidated. In the case of IAV, the prevailing model predicts that Mx1 as well as MxA
attach to the IAV vRNPs by forming oligomeric “ring-like” structures, thereby blocking
the activity of the viral polymerase (28–30). However, this mode of action does not
explain the pronounced inhibition of the IAV based minireplicon system, in which
replication occurs from vRNPs formed in the nucleus (31). Hence, MxA must act at an
additional step of the viral replication cycle. MxA is thought to exert a gatekeeper
function in the cytoplasm, blocking or modifying NP of incoming vRNPs and/or newly
synthesized NP in the cytoplasm of infected cells. Similarly, for MxB, evidence also
points to a gatekeeper function by preventing the nuclear import of genomic DNA of
human lentiviruses and herpesviruses into the nucleus (2, 6, 12). In addition, Lee and
colleagues have recently shown that MxA also acts as an inflammasome sensor protein
in human respiratory epithelial cells by recognizing IAV NP, thereby triggering inflam-
masome formation and interleukin 1 (IL-1) secretion (15).
The fact that Mx proteins inhibit a wide variety of RNA and DNA viruses at different
subcellular locations raises the question of whether (i) Mx proteins act via a largely
common mechanism and the observed virus specificity is a consequence of distinct
subcellular localization or (ii) Mx proteins act through different specific molecular
mechanisms.
To address these questions, we made use of human MxB predominantly accu-
mulating in the perinuclear region. This protein exerts antiviral activity against HIV
and herpesviruses but not against IAV (32). We reasoned that if the hypothesis of
a common antiviral mechanism between MxA and MxB was correct, a nuclear or
cytoplasmic form of MxB should also restrict IAV replication. We show here that MxB
retargeted to either the nucleus or the cytoplasm via a canonical NLS or the
N-terminal end of MxA indeed blocked IAV replication. Intriguingly, MxB retargeted
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to the nucleus still efficiently blocked HIV-1 infection, suggesting that MxB is able
to block HIV at different steps of its life cycle. These data underline the importance
of the subcellular localization of Mx proteins and suggest that Mx proteins act
through a common mechanism.
RESULTS
We first tested whether full-length MxB containing the NLS of the simian virus 40
(SV40) large T antigen at its N terminus (designated TMxB) would be expressed in
the cell nucleus. We transiently transfected HEp-2 cells with plasmids coding for
FLAG-tagged MxB, TMxB, and mouse Mx1 accumulating in the cell nucleus (24). The
SV40-NLS was attached to the N terminus of MxB since Mx proteins with modifi-
cations at their C-terminal ends (deletions or tags) lack GTPase activity and hence
antiviral activity against IAV (4, 5, 33). As expected, TMxB accumulated exclusively
in the nucleus, showing different size speckles and a weak staining throughout the
nucleus. Mx1 showed a similar punctuated pattern in the nucleus, omitting the
nucleoli (Fig. 1A). Since Mx1 assemblies have often been observed to be distributed
in juxtaposition to promyelocytic leukemia (PML) bodies in the nucleus (34, 35), we
tested whether this is also the case for TMxB. For this purpose, we cotransfected
HEp-2 cells with plasmids encoding FLAG-tagged TMxB, or mouse Mx1 and immu-
FIG 1 TMxB accumulates in the cell nucleus and is associated with promyelocytic leukemia (PML) bodies.
(A) HEp-2 cells were transfected with plasmids coding for FLAG-tagged wild-type (wt) MxB (MxB wt),
FLAG-tagged MxB containing an N-terminal nuclear localization signal (NLS), (TMxB), and FLAG-tagged
wild-type mouse Mx1 (Mx1 wt). Cells were fixed and immune stained with a mouse monoclonal antibody
specific for the FLAG tag. Images are representative for two independent experiments. (B) HEp-2 cells
were transfected with plasmids coding for nuclear MxB (TMxB) and wild-type Mx1. Cells were fixed and
immune stained with a mouse monoclonal antibody specific for the FLAG tag and with a rabbit
polyclonal PML antibody. PML bodies, promyelocytic leukemia bodies in the nucleus. Arrows depict
examples of TMxB-PML body in juxtaposition.
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nostained PML bodies and the FLAG peptide in parallel. Indeed, TMxB assemblies
were often found next to PML bodies (Fig. 1B), suggesting that the TMxB speckles
were not randomly distributed in the cell nucleus but were localized to distinct
subnuclear structures similar to those of Mx1 (35).
Next, we tested whether TMxB, by virtue of its nuclear localization, inhibits IAV
replication utilizing the IAV Kan1-based minireplicon system (36). For this purpose,
HEK293T cells were cotransfected with increasing amounts of plasmids (66 ng,
200 ng, and 600 ng) encoding either mCherry (negative control), wild-type (wt)
MxA, the inactive G-domain mutant MxA(D250N), wild-type MxB, TMxB, wild-type
mouse Mx1, and the inactive G-domain mutant Mx1(K49A) together with plasmids
encoding PB1, PB2, PA, and NP of the A/Thailand/1(KAN-1)/2004 (H5N1) strain, the
firefly luciferase reporter, and Renilla luciferase under a constitutive promoter. The
G-domain mutants of MxA and Mx1, previously shown to be inactive, were included
as negative controls (37, 38). Intriguingly, TMxB restricted IAV replication at least as
strongly as MxA, whereas MxB showed only marginal activity at high concentrations
of the transgene (Fig. 2A). As expected, Mx1 showed a strong inhibition of IAV,
whereas the G-domain mutants MxA(D250N) and Mx1(K49A) exhibited no inhibitory
activity. The activity of Renilla reniformis luciferase expressed under the control of
an constitutive promoter varied little and was not influenced by the Mx variant
expressed, demonstrating that none of the Mx variants exerted an unspecific
inhibitory effect (Fig. 2B) Hence, this experiment clearly demonstrates that MxB has
the capacity to restrict the replication of IAV when translocated to the nucleus.
In order to corroborate the antiviral potential of TMxB against IAV, we tested
whether TMxB would also exert anti-influenza activity in the context of infection.
We transfected HEK293T cells with plasmids encoding wild-type MxB, TMxB, and
MxA or control plasmids coding for mCherry or glutathione S-transferase (GST), and
infected the cells at 24 h posttransfection with 0.01 MOI of the IAV strains A/Seal/
Massachusetts/1/1980 (H7N7, designated rSC35M) or A/WSN/1933(H1N1). At 24 h
postinfection, the culture supernatants were harvested and subjected to plaque
assay analysis (Fig. 3). These data clearly indicate that TMxB expression restricted
IAV to a similar extent as MxA, resulting in a 12-fold reduction of rSC35M titers and
a 90-fold reduction of WSN titers. Cell viability assays performed in parallel revealed
that the observed reduction in titers was not due to cytotoxic effects of TMxB
expression (Fig. 3B). Furthermore, expression levels of the three Mx transgenes were
comparable (Fig. 3A, lower panels).
Thus, we could show that relocalization of MxB to the nucleus is essential for IAV
restriction. In the next step, we wanted to test whether relocalization of MxB to the
cytoplasm would also lead to a gain of antiviral activity against IAV. The signal
element of MxB targeting it to the outer surface of the nuclear envelope is located
in the unstructured region at the very N terminus of the protein (22), just preceding
the bundle signaling element (BSE) and GTPase domain (Fig. 4A). The N-terminal
end of MxB is not included in the schematic drawing, since it was deleted for
crystallization due to its unstructured nature (17). This is also the region where
major sequence differences between MxA and MxB are observed (39). For the long
isoform of MxB (perinuclear localization), this N-terminal region comprises 91 amino
acids, whereas in MxA only 43 amino acids are present (Fig. 4A). In order to alter the
subcellular localization and thus possibly the antiviral specificity, we generated two
types of MxA-MxB chimeras with interchanged N termini, namely, MxB(1-91)-
MxA(44-662) (designated N-MxB-MxA) and MxA(1-43)-MxB(92-715) (designated
N-MxA-MxB). Localization was monitored by immunofluorescence analyses in trans-
fected cells (Fig. 4B). Proteins harboring the MxB N terminus localized to the nuclear
envelope and were additionally seen in distinct punctate pattern in the cytoplasm
as previously observed (22). Remarkably, the N-MxB-MxA chimera showed only a
loose association with the nuclear envelope and localized predominantly in a
punctate pattern in the perinuclear region, while its GTPase-deficient counterpart
N-MxB-MxA(T103A) was strongly associated with the nuclear envelope (Fig. 4B). On
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the other hand, ectopic expression of N-MxA-MxB exhibited the typical cytoplasmic
distribution of MxA, whereas the GTPase-deficient variant N-MxA-MxB(T151A)
showed primarily a strong rod-like perinuclear staining. Intriguingly, destruction of
the GTPase activity appears to influence the subcellular localization of the chimeric
MxA-MxB proteins.
To assess the antiviral potential of these chimeras, we again performed viral plaque
assays as described above. In addition to the anti-IAV activity of TMxB (13-fold inhibi-
tion), chimeric N-MxA-MxB also showed potent IAV restriction (42-fold inhibition) (Fig.
4C). N-MxB-MxA exhibited a less pronounced but still significant activity (8-fold reduc-
tion), again suggesting that the subcellular localization does play a crucial role. The viral
FIG 2 The nuclear variant of MxB (TMxB) exhibits restriction of IAV replication. (A) Minireplicon assay of 293T cells transfected
with plasmids encoding the minireplicon constituents and increasing amounts of FLAG-mCherry or the indicated FLAG-Mx
proteins. Cells were lysed and a dual-luciferase assay was performed. Values are presented in percent firefly luciferase activity
normalized to Renilla luciferase relative to the mCherry control for each individual condition (66 ng, 200 ng, and 600 ng). Values
of mCherry-expressing samples are set to 100%. Data are represented as mean  standard deviation (SD) of triplicates. The
experiment was performed in biological triplicates. Western blot analysis was carried out with pooled lysates for each
condition, and immunostaining was performed with the indicated antibodies (bottom). (B) Renilla luciferase activity in the
minireplicon assays shown in panel A. Data are represented as mean  SD of triplicates.
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restriction was completely abrogated when the GTPase activity of these chimeras was
destroyed by introducing mutations into their G-domain (T103A for MxA and T151A for
MxB) (Fig. 4C). These data indicate that MxB exerts its anti-IAV activity by a similar
molecular mechanism to that of MxA, whose anti-IAV activity is strictly dependent on
its GTPase activity (37).
Goujon and colleagues have previously shown that the N-MxB-MxA chimera accu-
mulating in the perinuclear region efficiently restricted HIV infection, whereas the
cytoplasmic N-MxA-MxB variant showed no anti-HIV activity (22), These findings dem-
onstrated that there is a clear correlation between subcellular localization of MxB and
its anti-HIV activity (22). Therefore, we expected that TMxB residing exclusively in the
cell nucleus would lose anti-HIV activity. To test this hypothesis, we transfected HeLa
cells with plasmids coding for MxA, MxB, TMxB, N-MxA-MxB, N-MxB-MxA, and the
GTPase-deficient variants N-MxA-MxB(T151A) or N-MxB-MxA(T103A) and subsequently
transduced them with a VSV-G-pseudotyped HIV-green fluorescent protein (GFP) re-
FIG 3 TMxB blocks IAV infection. (A) Plaque assay titration of supernatants harvested from 293T cells transiently transfected
with plasmids coding for the indicated control protein or FLAG-Mx proteins and infected with a multiplicity of infection (MOI)
of 0.01 for 24 h. Supernatants were titrated on MDCK cells. Data are represented as mean  standard error of the mean (SEM)
of duplicates. Bottom panels show expression control. Samples were harvested at the same time as supernatants were
collected for the plaque assay. Western blot analysis was performed using the indicated antibodies (bottom panel). Data are
representative for two independent experiments. (B) CellTiter-Glo cell viability assay. 293T cells were transfected as in panel
A and cells were lysed at the same time as supernatant was collected for the plaque assay from an identical plate.
Luminescence was measured, and absolute values were plotted. Data are represented as mean  SEM of duplicates. P  0.05;
Student’s t test.
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FIG 4 MxB with the N terminus of MxA relocalizes to the cytoplasm and acquires anti-IAV activity. (A) Top: graphical representation of MxA
and MxB. Middle: crystal structure of MxA (28-amino-acid deletion in loop L4; PDB identifier [ID] 3SZR) and MxB (83-amino-acid deletion
at the N terminus; PDB ID 4WHJ). Bottom: alignment of the amino acid sequence of the N termini of MxA and MxB. (B) Subcellular
localization of MxA-MxB chimera. HEp-2 cells were transfected with plasmids expressing the indicated MxA or MxB variants or chimera.
Fixed cells were immunostained with a monoclonal mouse anti-MxA or anti-MxB antibody. Shown are representative images of 2
independent experiments. (C) IAV replication capacity in the presence of MxA, MxB, TMxB, and the indicated MxA-MxB chimera. 293T cells
were transiently transfected with plasmids coding for the indicated proteins for 24 h and were subsequently infected with WSN at an MOI
of 0.01 for 24 h. Protein expression was controlled by immunoblot analysis. Supernatant was transferred to MDCK cells and viral titers were
determined 24 h postinfection. Data are representative for three independent experiments. Data are represented as mean  SD of
(Continued on next page)
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porter virus. Surprisingly, TMxB exhibited a strong anti-HIV activity similar to that of
MxB, N-MxB-MxA, and its GTP-deficient variant (Fig. 4D). As expected, the mCherry
control, MxA, and the N-MxA-MxB variants did not restrict HIV (Fig. 4D). Hence, the data
corroborate the suggestion that MxB has the capacity to restrict HIV at multiple steps
(40, 41).
Although many studies have demonstrated that MxA targets NP, a direct interaction
of MxA with NP has not been observed so far (42–44). The general assumption is that
oligomeric MxA only transiently interacts with NP to exert its anti-IAV function. How-
ever, the dimeric mutants of MxA [like MxA(R640)] are able to form stable complexes
with NP (44). Since MxB appears to exist predominantly as a dimer (17), we next tested
whether MxB has also the capacity to form stable complexes with NP. For this purpose,
we transiently transfected HEp-2 cells with plasmids encoding MxB wt and TMxB. As
controls, we included plasmids coding for MxA wt, MxA(R640A), and the two GTPase-
deficient MxA mutants MxA(T103A) and MxA(D250N). At 24 h posttransfection, the cells
were infected with WSN at an MOI of 5 for 6 h, and the lysates were subjected to
coimmunoprecipitation (co-IP) experiments using a monoclonal mouse anti-NP anti-
body (Fig. 5A). Surprisingly, wild-type MxB, as well as TMxB, efficiently coprecipitated
with viral NP, indicating that MxB has indeed the capacity to form stable complexes
with NP, although independently of its subcellular localization (Fig. 5A). Hence, the
capacity of MxB to form a complex with NP is not sufficient for its anti-IAV activity, and
other parameters like stoichiometry and additional interactors appear to play a crucial
role. As expected, MxA(R640A) formed stable complexes with viral NP, while MxA wt
and the antivirally inactive GTPase-deficient mutants MxA(T103A) and MxA(D250N) did
not coprecipitate with NP.
Next, we tested whether the MxA-MxB chimera would also form stable complexes
with NP. To this end, we cotransfected plasmids encoding MxB wt, TMxB, N-MxA-MxB,
N-MxB-MxA, and their GTPase deficient variants NMxA-MxB(T151A) and N-MxB-MxA
(T103A) with an expression plasmid coding for the NP of the avian Kan-1 strain (Fig. 5B).
The data show that MxB and TMxB were efficiently coprecipitated with NP, indicating
that MxB has the capacity to form stable complexes with ectopically expressed NP in
the absence of other viral proteins. In contrast, irrespective of their anti-IAV activity,
none of the MxA-MxB chimeras coprecipitated with NP, again emphasizing the notion
that for Mx proteins the formation of stable complexes with NP is not a prerequisite for
anti-IAV function.
Next, we tested whether the stable complexes between TMxB and NP could also be
observed microscopically. For this purpose, we cotransfected HEp-2 cells with expres-
sion plasmids coding for FLAG-TMxB and NP (WSN). The cells were fixed at 24 h
posttransfection and subjected to immunostaining with antibodies specific for the
FLAG tag and for NP. The data show colocalization (yellow staining) of TMxB and NP
throughout the nucleus, with the exception of the TMxB assemblies. This finding
suggests that colocalization and thus potential interaction of TMxB and NP occurs
predominantly at regions were TMxB is evenly distributed and not in the form of large
aggregates (Fig. 5C).
Since Mx proteins such as Mx1 and TMxA, which localize to the nucleus, inhibit IAV
replication at or before the primary transcription of viral mRNAs (4), we tested whether
this also applies for TMxB. We transiently transfected HEK293T cells with plasmids
encoding mCherry, GST, Mx1, the G-domain mutant Mx1(K49A), MxA, MxB, or TMxB and
infected the cells with an MOI of 5 of the avian strain rSC35M for 6 h in the presence
or absence of cycloheximide (CHX). In the presence of cycloheximide IAV, vRNPs are still
FIG 4 Legend (Continued)
triplicates. P  0.0001; Student’s t test. (D) HIV-1 reporter virus replication capacity in the presence of MxA, MxB, TMxB, and the indicated
MxA-MxB chimera. HeLa cells were transiently transfected with expression plasmids coding for the indicated proteins. At 24 h
posttransfection, cells were infected with VSV-G-pseudotyped HIV-1 NL-Luc reporter virus. Luciferase assay was performed at 48 h
postinfection, and reporter activity is shown relative to mCherry. Data are represented as mean  SD of duplicates. Data are representative
for three independent experiments.
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able to enter the nucleus and to produce viral transcripts by the vRNP-associated viral
polymerase. However, later steps are blocked by the translational inhibition exerted by
cycloheximide (45). Overall mRNA levels were thus reduced in CHX-treated versus
dimethyl sulfoxide (DMSO)-treated samples since the viral proteins PB1, PB1, PA, and
NP, which are crucial for viral genome replication, are not translated. As expected, viral
mRNA levels were 35- to 100-fold lower in CHX-treated samples compared to those in
DMSO-treated controls (data not shown). Synthesis of viral mRNA was determined by
reverse transcription-quantitative PCR (RT-qPCR) with primers specific for PB2. Indeed,
TMxB inhibited viral RNA synthesis at a step prior to or during primary transcription to
a very similar extent as that of Mx1 (Fig. 6). As expected, Mx1(K49A), which lacked a
functional G domain, failed to inhibit viral mRNA synthesis in the presence or absence
of cycloheximide (Fig. 6).
FIG 5 MxB forms a stable complex with NP. (A) HeLa cells were transfected with plasmids encoding the indicated Mx
proteins. At 24 h posttransfection, cells were infected with WSN at an MOI of 5 for 6 h. Cells were lysed, and viral NP was
immunoprecipitated (IP) from lysates using a mouse monoclonal anti-NP antibody. The resulting complexes were
subjected to Western blot analysis using the indicated antibodies. In addition, whole-cell lysates (WCL) were also
monitored for expression of Mx, NP, and actin by Western blot analysis. (B) HEp-2 cells were transfected with plasmids
coding for the indicated Mx proteins and either a Kan1 NP-expressing plasmid or an empty vector. At 24 h posttrans-
fection, cells were lysed and the IP was performed as in panel A. (C) HEp-2 cells were transfected with plasmids coding
for FLAG-TMxB and WSN NP. Cells were fixed and stained with a rabbit antibody specific for the FLAG tag and a mouse
monoclonal antibody specific for IAV NP.
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The fact that Mx proteins, specifically MxA, are able to exhibit a very broad antiviral
specificity, inhibiting many RNA as well as DNA viruses at different steps of their
replication cycle, suggests that Mx proteins are multifunctional proteins that exert
different strategies to block viral replication. For instance, MxA blocks the replication of
viruses as diverse as VSV and HBV at different steps of their replication cycle (reviewed
in references 1 and 3). Moreover, Mx proteins can be found in different subcellular
compartments. Human MxA resides in the cytoplasm, where it is partially associated
with internal membranes, particularly with the smooth endoplasmic reticulum, whereas
the human MxB accumulates primarily in the perinuclear region associated with the
outer membrane of the nucleus but can also be found in the cytoplasm (6, 13, 14, 18).
In this study, we addressed the question whether the apparent diversity of antiviral
activities of Mx proteins is a consequence of distinct subcellular localizations rather
than of a multitude of molecular mechanisms. To test this hypothesis, we employed the
human MxB protein with well-defined antiviral activities against HIV, HSV, and cyclo-
philin A-dependent flaviviruses (7–9, 11, 26, 27) but not against IAV (2, 6, 11). We
reasoned that redirecting MxB into the nucleus by attaching a classical NLS (termed
TMxB) should enable it to block the replication of IAV, which occurs in the nucleus. The
fact that we often found TMxB assemblies in juxtaposition with PML bodies, a feature
previously noted for Mx1, strongly suggests that TMxB accumulates in distinct nuclear
domains (Fig. 1B) (34, 35). Indeed, ectopic expression of TMxB but not of MxB efficiently
blocked the expression of a luciferase reporter gene driven by the minireplicon system
FIG 6 Primary transcription of IAV is inhibited by TMxB. (A) 293T cells were transfected with plasmids coding for the indicated
control or FLAG-Mx proteins and infected with rSC35M(H7N7) at an MOI of 5 for 6 h. RNA was isolated and reverse transcribed
into cDNA using random primers. RT-qPCR analysis was performed, and PB2 mRNA normalized to GAPDH mRNA is shown. Cells
were pretreated with 100 g/ml cycloheximide (CHX) or with the same volume of solvent (DMSO) for 1 h prior to infection.
Where indicated, infection was carried out in the presence of CHX. Values are relative to the mCherry control, which was set
to 100%. Data are represented as mean  SEM of triplicates. (B) Western blot analysis of 293T cells transfected and lysed at
the same time as those in panel A. Immunostaining was performed with the indicated antibodies.
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based on the avian IAV strain Kan1, indicating that MxB has the capacity to interfere
with IAV replication when located in the nuclear compartment (Fig. 2). Moreover, TMxB
also strongly restricted infection by IAV strains of avian (rSC35M), as well as that by a
human-origin strain (WSN) (Fig. 3).
If the subcellular localization of the MxB protein indeed represented a major
determinant of its antiviral specificity, MxB should also exert anti-IAV activity in the
cytoplasm. Ectopic expression of a chimeric MxA(1-43)-MxB(92-715) protein containing
the N-terminal 43 amino acids of MxA in place of the N-terminal 91 amino acids of MxB
(Fig. 4A) revealed that this is indeed the case. This MxA/MxB chimera localized through-
out the cytoplasm as wild-type MxA and very efficiently restricted WSN replication (Fig.
4B and C). The anti-IAV activity of this protein was strictly dependent on its GTPase
activity, indicating that the observed restriction was indeed the result of the activity of
MxB. Interestingly, the reverse chimera MxB(1-91)-MxA(44-662) containing the 91
N-terminal amino acids of MxB also exhibited a partial anti-IAV, activity as previously
shown (22) (Fig. 4C). This restriction is also dependent on the GTPase activity of this
protein (Fig. 4C). However, immunofluorescence imaging revealed that this chimera
was less tightly associated with the nuclear envelope than was wild-type MxB and that
it located primarily to the perinuclear region of the cytoplasm (Fig. 4B), again empha-
sizing the importance of the subcellular localization of MxB for its antiviral specificity.
Previous studies by Goujon and colleagues assessing the anti-HIV-1 activity of
MxA-MxB chimeras also observed a strong correlation between subcellular localization
of MxB and anti-HIV-1 function, supporting the evidence for a gatekeeper function of
MxB at nucleopores (22). However, our surprising finding that nuclear TMxB blocks
HIV-1 does not fit with the proposed gatekeeper function (Fig. 4D). This finding implies
that MxB also has the capacity to inhibit HIV-1 replication in the nucleus. To that end,
Busnadiego and colleagues previously suggested that MxB has the capacity to inhibit
HIV-1 at additional steps of its life cycle (40, 41).
Since the antiviral activities of Mx1 and MxA are associated with a transient
interaction with their viral target NP (28, 42–44), it came as no surprise that MxB has the
capacity to bind NP (Fig. 5). The fact that MxB not only formed a complex with NP in
IAV-infected cells but also in cells ectopically expressing NP indicates that MxB interacts
directly with NP, hence not requiring the presence of other viral factors. (Fig. 5A and B).
Intriguingly, we observed that wild-type MxB was able to form a stable complex with
NP, unlike MxA, which can only stably interact with NP in the dimeric state [variants
MxA(R640A) or MxA(L617D)] but not in its wild-type form that exists as a tetramer. The
fact that MxB appears to predominantly form dimers (17) most likely explains this
apparent difference. The observation that TMxB and NP colocalized throughout the
nucleus, with the exception of the TMxB aggregates, suggests that the TMxB-NP
interaction does not occur at the large MxB assembly sites. This would fit with the
hypothesis that Mx assemblies may represent a nonactive storage form (46).
The capacity of MxB to interact with NP irrespective of its subcellular localization
suggests that binding of MxB to NP is not sufficient for blocking IAV replication. It is
conceivable that Mx proteins recruit auxiliary factors such as the nuclear export protein
UAP56 at distinct subcellular localizations to exert their full antiviral activity and
specificity (47–49).
For MxA, the disordered loop L4 (amino acids 533 to 572) plays a decisive role for
the recognition of the NP proteins of IAV and Thogoto virus (THOV) as targets (39, 50,
51). In particular, position F561 plays a crucial role for the antiviral activity against IAV
and THOV (39, 51). The L4 C-terminal part of MxB shows only limited sequence similarity
to the one of MxA (22) and has a 2-amino-acid extension. Nevertheless, it is conceivable
that MxB targets the viral NP protein via loop L4, but this remains to be demonstrated.
As expected, expression of TMxB reduced the synthesis of primary viral PB2 mRNA
to a similar extent as that of murine Mx1, strongly suggesting that TMxB, like Mx1,
interfered directly with viral mRNA transcription by blocking the activity of the viral
polymerase complex in the nucleus (Fig. 6) (35, 52). Surprisingly, cells expressing
wild-type MxA in the cytoplasm also showed reduced levels of viral primary transcripts.
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It was previously shown that MxA can inhibit IAV replication at two different steps,
namely, (i) during cell entry by blocking incoming vRNPs in the cytoplasm preventing
nuclear import of vRNPs (53, 54) or (ii) by interfering with the integrity or transport of
newly synthesized NP, a step following primary viral mRNA synthesis (32, 44). It is
therefore conceivable that in this experimental setting, overexpression of MxA led to a
pronounced block of vRNP import into the nuclei of infected cells, preventing initial
viral mRNA synthesis.
Our findings revealed that MxB acquired potent inhibitory activity against IAV when
redirected to subcellular compartments where murine Mx1 or human MxA have been
shown to block IAV replication. The notion that interaction of MxB with the viral target
protein NP is not sufficient for restricting IAV suggests the involvement of auxiliary
factors residing at distinct subcellular compartments. It will be interesting to elucidate
the contribution of these proteins to the antiviral activities and viral specificities of Mx
proteins.
MATERIALS AND METHODS
Cell lines. All cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal calf serum (FCS), 1 mg/ml penicillin/streptomycin and 2 mM GlutaMax (complete DMEM;
Thermo Fisher Scientific) at 37°C and 5% CO2. HEp-2 (HeLa-derived human epithelial cells), HeLa, and
HEK-293T (human embryonic epithelial kidney cells) were purchased from ATCC.
Plasmids. As previously described, MxA wild-type cDNA was cloned into pcDNA3.1()neo (Invitro-
gen) (55). MxA(R640A) cDNA in the pcDNA3.1()neo plasmid was kindly provided by Georg Kochs
(Freiburg, Germany). MxA mutant D250N was generated using the QuikChange II site-directed mutagen-
esis kit (Agilent). Primers were designed using PrimerX (http://www.bioinformatics.org/primerx/) with the
QuikChange protocol.
MxB cDNA with or without an N-terminal FLAG peptide sequence or MxB cDNA with an N-terminal
large T-antigen NLS peptide with or without a FLAG peptide were cloned into pcDNA3.1()neo
(Invitrogen) using the NotI and XbaI restriction sites. Plasmids encoding FLAG-Mx1 or FLAG-Mx1(K49A)
were previously described (37). The TMx1-encoding plasmid was described previously (4). Primers were
designed using PrimerX with the QuikChange protocol.
gBlocks for untagged MxA-MxB chimera were synthesized by Integrated DNA Technologies (IDT) and
cloned into the multiple-cloning site of pcDNA3.1()neo. T103A and T151A mutants were generated
using the QuikChange II site-directed mutagenesis kit (Agilent). Primers were designed using PrimerX
with the QuikChange protocol.
Viruses. Infection experiments were carried out using influenza A/Seal/Massachusetts/1/1980
H7N7 (rSC35M) or A/WSN/1933(H1N1) (WSN) strains. Infections were performed in phosphate-
buffered saline (PBS) supplemented with 0.02 mM Mg2, 0.01 mM Ca2, 0.3% bovine serum albumin
(BSA), and 1% penicillin/streptomycin (PBSi) for 1 h at 37°C. Inoculum was removed, cells were
washed with PBS, and DMEM supplemented with 20 mM HEPES, 0.2% BSA, 1 mg/ml penicillin/
streptomycin and 2 mM GlutaMax (Thermo Fisher Scientific) (piDMEM) was added.
Immunofluorescence assay. HEp-2 cells were seeded in 24-well format on glass cover slides. After
transfecting with jetPrime (Polyplus-transfection), cells were fixed with 3% paraformaldehyde (PFA) in
PBS for 10 min at room temperature and permeabilized with 0.1% or 0.5% Triton X-100 in PBS for 10 min
at room temperature. Staining was performed in PBS with 5% goat serum for 1 h at RT with mouse
anti-MxA (ɑ-MxA) (hybridoma ab143, 1:5, in house), mouse -MxB (sc-271527, 1:50; Santa Cruz Biotech-
nology), mouse -FLAG M2 (F1804, 1:1,000; Sigma), rabbit -FLAG (F7425, 1:1,000; Sigma), or mouse -NP
(hybridoma HB65, 1:5, ATCC).
Minimal replicon reconstitution assay. The minireplicon assay has been described before (31).
Basically, pcDNA3.1()neo vectors harboring cDNA sequences of the viral polymerase subunits PB1 and
PB2 and PA and viral NP derived from the A/Thailand/1(KAN-1)/2004 (H5N1) strain were transfected into
293T cells. Additionally, the firefly luciferase (FFLuc) reporter plasmid pPOLI-Luc-RT (42) and the consti-
tutively active Renilla reniformis luciferase (RRLuc) plasmid pRL-SV40-Rluc (Promega) as a readout and for
transfection efficiency were cotransfected using jetPrime (Polyplus-transfection) according to the man-
ufacturer’s instructions. PB1, PB2, and PA (10 ng) and NP, FFLuc, and RRLuc (50 ng) plasmids plus various
amounts of plasmids coding for Mx proteins were transfected. For the readout, cells were lysed 24 h after
transfection in 60 l of 1 passive lysis buffer and incubated at room temperature for 15 min on a shaker.
A dual-luciferase readout was performed using the Dual-Luciferase reporter assay system (Promega).
Lysate (15 l) was mixed with 45 l luciferase assay reagent II (LARII) and immediately read on a Perkin
Elmer Envision 2104 plate reader for the Firefly luciferase signal; an additional 45 l of Stop & Glo was
added for the Renilla luciferase readout.
Western blot staining was performed in 2.5% milk in PBS-Tween for 1 h at RT using rabbit -FLAG
(1:1,000, F7425; Sigma), rabbit -NP (1:10,000; serum in house), mouse -actin (1:1,000, sc-47778; Santa
Cruz Biotechnology), and mouse -Mx (1:20, in house, ab143).
Plaque assay. 293T cells were transfected with plasmids coding for MxA and MxB variants or GST or
mCherry as controls. At 24 h postinfection, the cells were infected with rSC35M or WSN at a multiplicity
of infection (MOI) of 0.01 for 24 h. Supernatant was harvested, and MDCK cells were subsequently
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inoculated with diluted supernatant (from 101 to 106 in 1:10 dilution steps) for 1 h at RT. Inocula were
aspirated, and a 1% Avicel in H2O overlay was applied. At 28 h postinfection, the Avicel was aspirated and
the cells were fixed for 10 min with 3% PFA and stained for 15 min with 0.1% crystal violet in 10%
methanol.
CellTiter-Glo assay. 293T cells were transfected and at 48 h posttransfection, half the volume of the
medium was aspirated. An equal volume (as aspired medium) of Cell-Titer-Glo (Promega) reagent was
added to the wells, incubated for 2 min at room temperature on a shaker and for an additional 10 min
without shaking, and luminescence was measured on a Perkin Elmer Envision 2104 plate reader.
Coimmunoprecipitation. HEp-2 cells were transfected with ViaFect (Promega) according to the
manufacturer’s instructions. At 24 h posttransfection, cells were lysed in 300 l of lysis buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM MgCl2, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 50 mM
-glycerophosphate, 100 nM iodoacetamide, and 1 Roche cOmplete protease inhibitor cocktail) in the
dark on ice for 30 min. Lysates were homogenized using QiaShredder columns (Qiagen).
In the case of a coimmunoprecipitation (co-IP) experiment from infected cells, HeLa cells were
infected at 24 h after transfection (see above) with WSN at an MOI of 5 for 6 h.
Aliquots (100 l) of each lysate were incubated with the antibody -NP (in-house, 50 l, HB65,
hybridoma) at 4°C overnight on a rotating wheel. In the infection IP, lysates were incubated 5 h with
antibodies (either -NP [see above] or 1 g mouse -FLAG [F1804; Sigma]). Dynabeads protein G
magnetic beads (Thermo Fisher Scientific) (20 l per sample) were preadsorbed overnight at 4°C on a
rotating wheel using untransfected HEp-2 cell lysate. Preadsorbed beads were washed once with lysis
buffer and incubated with the lysates for 1 h at 4°C on a rotating wheel. Beads were washed five times
with 0.5 ml lysis buffer. Beads were briefly vortexed between the washing steps. Proteins were eluted
from the beads with 20 l of 1 Laemmli buffer at 95°C for 10 min. Lysates were analyzed by Western
blotting using rabbit -NP (1:10,000; in-house), mouse -FLAG (F-3165, 1:1,000; Sigma), rabbit -FLAG
(F7425, 1:1,000; Sigma), rabbit -actin (A2103, 1:1,000; Sigma), mouse -MxB (271527, 1:500; Santa Cruz
Biotechnology), or rabbit -MxA (H00004599_D01P, 1:1,000; Abnova).
Luciferase assay with VSV-G-pseudotyped HIV-1 NL-Luc reporter virus. HeLa cells were trans-
fected with 75 ng of expression plasmid and 425 ng of puromycin resistance plasmid. At 24 h posttrans-
fection, cells were infected with the NL-Luc virus stock (1:27 dilution) in Opti-MEM reduced serum
medium (Life Technologies) plus 8 g/ml Polybrene (Sigma-Aldrich) and 1 g/ml puromycin (InvivoGen)
for 90 min at 37°C and 5% CO2. The inoculum was removed, and the cells were washed with PBS and
incubated at 37°C and 5% CO2 for 48 h in growth medium (complete DMEM) with 20% FCS plus 1 g/ml
puromycin to ensure survival and expression of reporters in transfected cells only. Luciferase readout was
performed with the BrightGlo luciferase assay system (Promega) on an Envision 2104 plate reader (Perkin
Elmer) according to the manufacturer’s instructions.
qRT-PCR. 293T cells were transfected using jetPrime (Polyplus-transfection) according to the man-
ufacturer’s instructions. At 24 h posttransfection, cells were pretreated for 1 h with 100 g/ml cyclohex-
imide (CHX) or dimethyl sulfoxide (DMSO). Cells were inoculated with virus in PBSi for 1 h at 37°C with
rSC35M or SFV V42 at an MOI of 5. The inoculum was aspirated and piDMEM was added. At 5 h
postinfection, the medium was removed and cells were lysed with 200 l TRIzol reagent (Thermo Fisher
Scientific) per well of a 24-well plate. After the addition of 40 l of chloroform, the samples were mixed
thoroughly by inverting the tubes several times and then centrifuged at 13,000  g at 4°C for 15 min. The
resulting upper aqueous phase (120 l) was transferred to a new tube, and RNA extraction was
subsequently performed using the RNeasy minikit (Qiagen) starting with the addition of 1 volume of 70%
ethanol (EtOH). cDNA synthesis was performed with 1 g RNA using SuperScript III reverse transcriptase
(Thermo Fisher Scientific) and random primers. The quantitative PCR (qPCR) was performed with 2.5 l
of the 1:10 diluted cDNA and EvaGreen fluorescent nucleic acid dye in a total volume of 20 l. The
cycling conditions were as follows: initial denaturation, 95°C for 5 min; denaturation, 95°C for 15 s;
annealing and extension, 60°C for 60 s. A dissociation step starting at 55°C was added in the end to
confirm the specificity of the primers. The primer sequences are as follows: rSC35M PB2 forward primer,
5=-GCAATGGGCTTGAGGATT; rSC35M PB2 reverse primer, 5=-CAATCTCCTGGTTGCCTT; GAPDH forward
primer, 5-CTGGCGTCTTCACCACCATGG; and GAPDH reverse primer, 5-CATCACGCCACAGTTTCCCGG. The
fold change of PB2 mRNA normalized to GAPDH mRNA was calculated according to Pfaffl (56). In short,
first, the threshold cycle (ΔCT) of a given sample was calculated [CT(CHX)  CT(DMSO)], then ΔΔCT was
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